Articles by James C. Greenwood - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by James C. Greenwood

James C. Greenwood


Jim Greenwood is president and CEO of the Biotechnology Industry Organization, 1201 Maryland Ave. SW, Suite 900, Washington, DC 20024, tel. 202.962.9200.

Articles
Prescribing Caution for Biosimilars
April 2, 2013

Sound policies are needed to govern the substitution of interchangeable biologics.

Intellectual Property as the Foundation of Innovation
December 2, 2010

Supportive public policy is needed in order for innovation to flourish.

Delivering on the Promise of Biotechnology
April 2, 2010

The BIO convention, and healthcare reform, could re-energize biotech.

Healthcare Reform Requires Room for Innovation
January 2, 2010

To move from R&D to breakthrough drugs, biotech companies need policies that support innovation.

Progress Made on the Path to Biosimilars
October 2, 2009

BIO supports recent Congressional action toward a 12-year data exclusivity period for innovators.

Biotechnology in 2009
May 2, 2009

The president of BIO proposes the ingredients needed for industry growth.

Industry Leaders Debate Follow-on Biologics Pathway
May 2, 2009

The organizations' presidents discuss market exclusivity, approval processes, and pending legislation.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here